Bacillus Anthracis (Anthrax) Infection
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsBioThrax
Allergy TherapeuticsBioThrax
Allergy TherapeuticsBioThrax
Clinical Trials (3)
Total enrollment: 601 patients across 3 trials
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
Start: Jul 2012Est. completion: Jun 2013328 patients
Phase 4Completed
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Start: Jan 2013Est. completion: Dec 2014168 patients
Phase 2Completed
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Start: Dec 2010Est. completion: Jun 2012105 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.